Engaging Patients in the Design, Generation, and Use of Patient Experience Data, including Real World Data

GetReal Institute Summit



Hayley Chapman Senior Program Director PFMD





PFMD Purpose:

PFMD's goal is to improve global health by co-designing the future of healthcare for patients **WITH** patients.

46 Active Partners

Global Multi-stakeholder Reach made with patients







Build the Conditions and Enablers of Patient Engagement <u>_</u>

Build Patient Engagement in Digital Health & Data



Brought to you by PFMD.org

Patient Engagement & Patient Experience Data Project




Clarifying, integrating and streamlining the design, generation, analysis and decision-making about patient experience data (PED) through, and with, patient engagement (PE)

		Objectives		
1. Provide clarity , structure and alignment of PED	2. Create a common understanding and language	3. Ensure relevance and accessibility for all stakeholders in healthcare decision-making	4. Integrates PE through co-creation, as POs and patient experts contribute to development	5. Emphasizes the need to prioritize what is most important and meaningful for patients



Patient engagement needs to be active and meaningful



made with patients



Regulator's Definition of Patient Experience Data (PED)

Data collected by any individual or organization

Captures patients' experiences, perspectives, needs, and priorities related to (but not limited to):



"Input on which outcomes are important to them"



"Patient preferences for outcomes and treatments"



"The relative importance of any issue as defined by patients"

. Fei

"The symptoms of their condition and its natural history"

	-	-	
1	-	-	
- 1 1	1	1	V.
-11	L.	27	5
- V		_	7
	-	-	

"The impact of the conditions on their functioning and quality of life"




"Their experience with treatments"

Source: Section 569C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb-8c).




All must understand that patient experience data does not replace patient engagement



PE can support PED to ensure patient-centricity of measurement, contextualization of data, increased understanding of the evidence generated, and the co-creation of the design, generation, collection and analysis of PED.




Co-creation with 300+ individuals, from 45+ organizations, with 600+ insights





made with

2021-2022, PE & PED resources and tools increased awareness and provoked change





Global PED Navigator responds to 5 key questions resulting in 2 comprehensive and integrated templates

1. WHAT:

Highlight the needs that are most important to patients

2. HOW:

Review the approaches and methodologies available (and identify gaps) to measure these patient experiences

3. WHEN:

Consider when stakeholders are using this data and **4. WHY**

5. WHO:

Identify the stakeholders that are using PED

BETA Global Patient Exper Navigator	ience Data		The current matrix can I & families. In grey you o							patients	Somewhat	Not appropriate a oppropriate a opriate approa	pprooch redents		
Tools for mea outcomes tha	t matter to												stan		
patients & fan Share your feedback on Answer the public consi	this document.	o start.	Qualitative methods	PROS		ClinRO	3	ObsROs		PerfOs		DHTs (Dig Technolog			
Area of impact*	Specific impo	ict													
Mortality/survival	Mortality/surviv	/al													
	Objective signs														
symptoms	Subjective	BETA													
	Physical Emotional Social	8	Nobal Patient Experience Data lavigator nt Experience Dat		The Stakeholder process. The ma avoid duplicatio	rtrix gives	you the opportu								
	Role Cognitive Global Qo	use ti	hroughout the hcare process		Real World Data	6	Symptoms identification		Diagnosis		Treatment ch	olces	Therapy cycle	15	Disease progression or survivorship
	Perceived	Stake	holder			_									
	Treatment				Measure improvements in		Enhanced understanding		Personalized medicine/		Enrich treatment				
	Adverse er side effect	Patien	s, caregivers		health outcomes or quality of life		of the natural history of the disease or condition, including progression,		biomarkers		information guidance (6)				
	Direct cos				Inform research, p		severity, chronicit	sy.							Inform research, policy,
	Societal/c				education initiativ Unmet medical ne										education initiatives Unmet medical needs
Patient journey	Patient jos	Patien	it advocate		Defining patient-re added values and outcomes	elevant									United the data meets
* The "areas of impact / specific celaboration with an angoing in <u>lealth Council</u> and adapted the	poing initiative being led i			Enhanced underst of the natural hists disease or condition	ory of the										
		Health	care professionals		Inform healthoare setting Performance mon and assurance Unmet medical ne Enhanced underst of the natural hist disease or conditi Establish clinical g (6)	itoring reds canding cry of the on (6)	Enhanced under of the natural his disease or condition	tory of the	Personalized me biomarkers Enhanced under of the natural his disease or cond	standing					Inform healthcare priority setting Performance monitoring and assurance Unmet medical needs
					Characterise dise										
		Answer th	r feedback on this document is public consultation.			Citick to navigate to the next tool Overview document Tools to identify what outcomes matter to patients & families									
		Click here	to start.		Tools for me	Tools for measuring outcomes that matter to patients & families PED use throughout the drug development cycle PED use throughout the Healthcore process									





made wit

Patient experience data relevant for many stakeholders

Healthcare systems	Patient advocacy	Patients, caregivers	Regulators	Life sciences industry		
Healthcare priorities Performance monitoring Benchmarking Service improvement	Identify patient needs Shape new patient services Inform research Inform health policy argumentation	Inform shared decision-making Contextualize choices Understand experiences of others	Inform regulatory decisions Contextualize clinical evidence Post-marketing data Revise product labelling	Inform priority setting Pipeline and business decisions Value propositions Trial design		
HTAs organization	Clinical practice	Researchers	Funders	Payors		
Inform value assessments Input into scoping and early dialogues Broaden scope of evaluations	Quality improvement Shared decision making Identification of gaps in care and support	Inform priority setting Identification of meaningful outcomes Study design	Informing funding priorities Input into grant assessment criteria Input into research progress assessments	Inform priority setting Budget allocation Reimbursement decision-making		

made wi




2023 - Co-creating first version of multi-stakeholder Global PE & PED Navigator



Patient Engagement Quality Criteria



PE & PED Navigator (Phase II)





2023 - Exploring opportunities to consider Real World Data in relation to Patient Experience Data

Real-world data

- 1. Provide guidance on the "how and when" of PE for the generation and use of RWD
- 2. Capacity building tools/resources for patient organizations to collect RWD
- 3. Develop tools to increase awareness of importance of contributing data amongst HCPs and patients
- 4. Provide recommendations on the inclusion of patient experience data in the collection of RWD





PE and Patient Experience Data Questions? Want to chat?

Please provide your email address

bit.ly/3h8gkAm



MD.ora



made with patients

pfmd